Paul Schulz
Infectious Disease · Louisville, KYNPI 1649260993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $149,915 of the $189,377 with a category attached, or 79.2%. 21 manufacturers reported payments, led by Gilead at 51.8% of the total. Reporting peaked in 2019 at $74,060 and has fallen 53.5% since, to $34,403 in 2023. Among infectious disease clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $547.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$98K
- Merck$88K
- Theratechnologies Inc.$2K
- Abbott$466
- Mayne Pharma Commercial LLC$214
- Astellas Pharma US Inc$155
- plus $983 from 15 others
Across 17 payments — averaging $9036.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$91K
- Gilead$47K
- Merck$16K
What the payments were for
- Consulting fees$11,1306%
- Speaking & faculty fees$149,91579%
- Travel & lodging$21,81012%
- Food & beverage$6,3923%
- Education$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 171 | $98,186 |
| Merck | 97 | $87,709 |
| Theratechnologies Inc. | 7 | $1,664 |
| Abbott | 2 | $466 |
| Mayne Pharma Commercial LLC | 11 | $214 |
| Astellas Pharma US Inc | 6 | $155 |
| Johnson & Johnson(2 entities) | 7 | $128 |
| Viiv Healthcare Company | 9 | $127 |
| Shionogi Inc | 4 | $121 |
| Melinta Therapeutics, LLC | 6 | $115 |
| AbbVie | 7 | $114 |
| Comsort, Inc | 1 | $100 |
| Pfizer | 4 | $48 |
| Paratek Pharmaceuticals, Inc. | 3 | $48 |
| Insmed, Inc. | 3 | $46 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $35 |
| Dynavax Technologies Corporation | 2 | $26 |
| Medline Industries LP | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$30,641
- Descovy$30,398
- PNEUMOVAX 23$25,486
- GARDASIL$21,078
- VAXNEUVANCE$17,646
- GARDASIL 9$12,740
- Truvada$8,910
- Veklury$8,071
- VAQTA$7,122
- Sunlenca$6,030
- PROCLAIM$457
- SIVEXTRO$100
How this compares
$189,377 in reported general payments places this provider in the 95th percentile of 100 infectious disease providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 206 | $786,381 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $113,387 |
| DovatoDolutegravir Sodium/Lamivudine | 39 | $105,506 |
| TivicayDolutegravir Sodium | 25 | $56,713 |
| PrezcobixDarunavir/Cobicistat | 22 | $49,306 |
| ValacyclovirValacyclovir Hcl | 11 | $418 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $98,186 | $899,768231 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $127 | $162,21964 claims |
| Johnson & JohnsonPrezcobix | $128 | $49,30622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 100 infectious disease providers in Kentucky.
Other infectious disease in Louisville
- Julio RamirezLouisville$256K
- Martin GnoniLouisville$194K
- Tariq MehmoodLouisville$75K
- Anupama RaghuramLouisville$9K
- Barbara WojdaLouisville$7K
- Benjamin KlausingLouisville$7K
- Kamran AkhtarLouisville$4K
- Forest ArnoldLouisville$4K
- Mark BurnsLouisville$3K
- Kenechukwu ObiokoyeLouisville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.